Experts called results of the early-phase study “exciting” and “promising” after patients who had exhausted all other treatment options showed an impressive response. The drug, known as ONX–0801, was tested in 15 women with advanced ovarian cancer as …
An experimental new treatment for ovarian cancer led to a dramatic shrinking of tumors in a small, early-phase study. Researchers were testing a drug, known as ONX–0801, for safety, but found that tumors in half of the 15 women studied shrank during …
Scientists have made the biggest breakthrough in a decade in the treatment of advanced ovarian cancer . Seven out of 15 women taking new drug ONX–0801 in a trial run by London's Royal Marsden Hospital were told their tumours had shrunk dramatically.
A team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust tested the drug, known in the study as ONX–0801, in 15 women with ovarian cancer as part of a wider phase I clinical trial. Phase I trials are run in …
The trial was part of a larger study by the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust in London. ONX–0801 enters the cancer cells by mimicking folic acid – ovarian cancer has a large number of receptors for folic acid.
Researchers are hailing an experimental drug as a major advance in the treatment of ovarian cancer, which typically claims the lives of up to 1400 Australian women every year. The drug, known as ONX–0801, is being described as the biggest breakthrough …
NHS Choices: Ovarian cancer. The researchers, from the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust in London, wanted to establish whether the drug, known in the study as ONX–0801, was safe, so they tested it on a small …
The trial also found that because ONX–0801 targets cancer cells specifically, while leaving healthy cells alone, patients did not experience common side effects such as infections, diarrhoea, nerve damage and hair loss associated with traditional …
Cancer patients who had run out of other options responded well to the new drug in a medical advance which experts have hailed as “exciting” and “promising”. The drug – called ONX–0801 – was tested on 15 woman with advanced ovarian cancer in the first …
A new treatment for ovarian cancer has been hailed "highly promising" by researchers after it was found to significantly shrink tumours. Seven out of 15 women with advanced ovarian cancer, who had exhausted all other treatment options, saw their …
Current efforts to combat the ovarian cancer mainly focus on targeted therapies which try to match interventions with certain gene types. But researchers say the new ONX–0801 drug has could be of benefit a wide cohort of women with advanced ovarian …
ONX–0801 works by mimicking folic acid to enter the cancer cells, and then killing them by halting the action of a protein called hymidylate synthase. Because it targets cancer cells specifically, it carries none of the side effects associated with …
Only one in three women with the cancer will survive for more than ten years and it causes 4,000 deaths a year in Britain. Scientists at the Institute of Cancer Research have developed a compound, ONX–0801, that sneaks into the tumour by disguising …
(CHICAGO) — A new treatment for ovarian cancer has shown “promising” results in women who are in the advanced stages of the disease, according to the BBC. The drug, known as ONX–0801, shrunk tumors in more than half the patients who participated in …
The team tested the drug, ONX–0801, in 15 women with ovarian cancer as part of a wider phase I clinical trial. The drug had significantly shrunk tumors in seven of the patients who carried the specific molecule that the drug was created to target. Her …
